

The logo for DiaSorin, featuring the company name in white serif font on a dark blue rectangular background.

DIASORIN S.P.A. ANNOUNCES THE ACQUISITION OF THE BIOTRIN GROUP IN IRELAND

Diasorin makes further progress in the growth plan announced upon during the listing process, broadening further its product portfolio and strengthening its leadership as a supplier of specialty products for in vitro diagnostics.

Saluggia (Vercelli, Italy), Dublin (Ireland) July 9 – Mr. Carlo Rosa, Diasorin CEO - a company that operates in the global market for in vitro diagnostics - , announces the acquisition of Biotrin, an Irish Group, world leader in the diagnosis of maternal-fetal infections caused by Parvovirus. The overall payment, totally financed by existing credit lines, amounts to about 25 million euros, out of which about 22 million euros upfront and about 3 millions euros as retained amount to an escrow account for 24 months. The good cash generation of Biotrin and Diasorin will allow to reimburse in the short term the financial loan raised for the purpose of the acquisition.

Biotrin was founded in 1992 in Dublin, where its research, production and marketing operations are located. It has about 70 employees at a facility registered with the FDA in the United States.

In the fiscal year ended October 31, 2007¹, Biotrin reported consolidated revenues of about 10.3 million euros, consolidated EBIT of about 2.3 million euros (after about 1.0 million euros in amortization of goodwill) and consolidated net profit of about 1.7 million euros.

Over the past ten years, Biotrin has gained a global leadership position in the diagnosis of Parvovirus infections, in terms both of its commercial presence (estimated market share of 60%) and of the patents that protect its products in the United States and Europe. With regard to future growth, Biotrin signed a licensing agreements with the National Institutes of Health (NIH) in the United States securing exclusive rights to a series of patents that will be used to develop innovative products to assess the effectiveness of Human Papilloma Virus (HPV) vaccination. Market launch of these products is scheduled for the first quarter of 2009.

¹ Data reported accordingly with Irish GAAP.

The Biotrin acquisition is strategically significant for Diasorin because:

1. It will increase the profitability of the products currently marketed by Biotrin by switching from the existing system of third-party distributors to Diasorin's sales network, which is active in all of the main markets with direct commercial branches.

2. Following an accelerated product development program, it will enable Diasorin to develop on the Liaison technology some of the Biotrin products. The resulting access to the over 2,200 LIAISON systems currently installed at customer facilities will undoubtedly increase the use of these specialty products. Once they become available on the LIAISON system, these unique products will also help further differentiate the Diasorin product line from those of its competitors.

3. Thanks to the NIH license concerning products to monitor the effectiveness of Papilloma virus vaccination, it will enable Diasorin to add to its research pipeline a new family of products in an area that is experiencing rapid growth following the recent introduction in the United States and Europe of a series of new vaccines to prevent the occurrence of uterus cervix tumors caused by this virus.

“ With the agreement signed today,” said Gustavo Denegri, Diasorin Chairman, “ we are continuing along a growth path that is consistent with the guidelines provided to our shareholders at the time of the IPO, which calls for broadening our product portfolio with the addition of specialty products that are highly distinctive compared with those of our competitors.

About Diasorin

Diasorin S.p.A., an international player in the market for in vitro diagnostics, develops, produces and markets reagent kits for clinical laboratory diagnostics. The Diasorin Group comprises 12 companies based in Europe, the United States, Central and South America and Asia. It has more than 900 employees, including over 80 research and development specialists, and operates three manufacturing and research facilities in Saluggia (Vercelli, Italy), Dietzenbach (Germany) and Stillwater (USA). Thanks to its direct sales organization and an international network of over 80 independent distributors, the Group is present in more than 60 countries, offering a broad array of high quality products that includes comprehensive lines for each of the clinical segments in which the Group operates: infectious and viral diseases, management of bone and calcium related diseases, thyroid pathologies, oncology and fertility testing.

In 2007, Diasorin reported revenues of 202.3 million euros, EBIT of 46.1 million euros and a net profit of 25.2 million euros.

Additional information is available on our website: www.diasorin.com

Contacts:

Investor Relations Officer

Laura Villa

Diasorin S.p.A.

laura.villa@diasorin.it

+39 0161487532

+39 348 15 11 542

Press Office

Carolina Mailander

c.mailander@mailander.it

+39 335 655 56 51

Bruno Caprioli

caprioli@mailander.it

+39 335 590 14 02